High genetic diversity of ciprofloxacin-nonsusceptible isolates of Streptococcus pneumoniae in Poland

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 5, 2005, Pages 2126-2129

  Sadowy, Ewa ^a   Izdebski, Radosław ^a   Skoczyńska, Anna ^a   Gniadkowski, Marek ^a   Hryniewicz, Waleria ^a  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; GENETIC VARIABILITY; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; POLAND; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RESPIRATORY TRACT INFECTION; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; PNEUMOCOCCAL INFECTIONS; POLAND; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 18244393164     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.5.2126-2129.2005     Document Type: Article

References (33)

1. Alou, L., M. Ramirez, C. García-Rey, J. Prieto, and H. de Lancastre. 2001. Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones. Antimicrob. Agents Chemother. 45:2955-2957.
2. 87. Antimicrob. Agents Chemother. 45:1994-2000.
3. Bast, D. J., D. E. Low, C. L. Duncan, L. Kilburn, L. A. Mandell, R. J. Davidson, and J. S. C. de Azavedo. 2000. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44:3049-3054.
4. Broskey, J., K. Coleman, M. N. Gwynn, L. McCloskey, C. Traini, L. Voelker, and R. Warren. 2000. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 45(Suppl. S1):95-99.
5. Brown, S. D., D. J. Farrel, and I. Morrisey. 2004. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US study. J. Clin. Microbiol. 42:4980-4987.
6. Brueggemann, A. B., S. L. Coffman, P. Rhomberg, H. Huynh, L. Almer, A. Nilius, R. Flamm, and G. V. Doern. 2002. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46:680-688.
7. Canton, R., M. Morosini, M. C. Enright, and I. Morrissey. 2003. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J. Antimicrob. Chemother. 52:944-952.
8. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-238.
9. Davies, T. A., R. Goldschmidt, S. Pfleger, M. Loeloff, K. Bush, D. F. Sahm, and A. Evangelista. 2003. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J. Antimicrob. Chemother. 52:168-175.
10. Enright, M. C., and B. G. Spratt. 1998. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144:3049-3060.
11. Fukuda, H., and K. Hiramatsu. 1999. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:410-412.
12. Garcia-Rey, C. L., L. Aguillar, and F. Baquero. 2000. Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain. Antimicrob. Agents Chemother. 44:3481-3482.
13. Gill, M. J., N. P. Brenwald, and R. Wise. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:187-189.
14. Gillespie, S. H., L. L. Voelker, J. E. Ambler, C. Traini, and A. Dickens. 2003. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb. Drug Res. 9:17-24.
15. Goldsmith, C. E., J. E. Moore, P. G. Murphy, and J. E. Ambler. 1998. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. J. Antimicrob. Chemother. 41:420-421.
16. Goosens, H., M. Ferech, R. V. Stichele, M. Elseviers, and the ESAC Project Group. 2005. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365:579-587.
17. Ho, P. L., R. W. H. Yung, D. N. C. Tsang, T. L. Que, M. Ho, W. H. Seto, T. K. Ng, W. C. Yam, and W. W. S. Ng. 2001. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 48:659-665.
18. Janoir, C., V. Zeller, M.-D. Kitzis, N. J. Moreau, and L. Gutmann. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
19. Johnson, C. N., W. H. Benjamin, Jr., S. A. Moser, S. K. Hollingshead, X. Zheng, M. J. Crain, M. H. Nahm, and K. B. Waites. 2003. Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America. J. Clin. Microbiol. 41:2458-2464.
20. Jones, M. E., D. F. Sahm, N. Martin, S. Scheuring, P. Heisig, C. Thornsberry, K. Köhrer, and F.-J. Schmitz. 2000. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44:462-466.
21. Jones, M. E., J. A. Karlowsky, R. Blosser-Middleton, I. A. Critchley, E. Karginova, C. Thornsberry, and D. F. Sahm. 2002. Longitudinal assessment of antipneumococcal susceptibility in the United States. Antimicrob. Agents Chemother. 46:2651-2655.
22. Klugman, K. P. 2002. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur. Respir. J. 20(Suppl. 36): S3-S8.
23. Lefevre, J. C., G. Faucon, A. M. Sicard, and A. M. Gasc. 1993. DNA fingerprinting of Streptococcus pneumoniae strains by pulsed-field gel electrophoresis. J. Clin. Microbiol. 31:2724-2728.
24. Montanari, M. P., E. Tili, I. Cochetti, M. Mingoia, A. Manzin, and P. E. Varaldo. 2004. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy. Microb. Drug Resist. 10:209-217.
25. Nagai, K., T. A. Davies, G. A. Pankuch, B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 2000. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:2740-2746.
26. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 6th ed. M7-A6, M100-S13. National Committee for Clinical Laboratory Standards, Wayne, Pa.
27. Oh, W. S., J. Y. Suh, J.-H. Song, K. S. Ko, S.-I. Jung, K. R. Peck, N. Y. Lee, Y. Yang, A. Chongthaleong, C.-H. Chiu, A. Kamarulzaman, N. Parasakthi, M. K. Lalitha, J. Perera, T. T. Yee, G. Kumarasinghe, C. C. Carlos, and the ANSORP Study Group. 2004. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae from Asian countries: ANSORP study. Microb. Drug Resist. 10:37-42.
28. Pan, X.-S., and L. M. Fisher. 1996. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178:4060-4069.
29. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
30. Pankuch, G. A., B. Bozdogan, K. Nagai, A. Tambić- Andrašević, S. Schoenwald, T. Tambić, S. Kalenić, S. Pleško, N. K. Tepeš, Z. Kotarski, M. Payerl-Pal, and P. C. Appelbaum. 2002. Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia. Antimicrob. Agents Chemother. 46:2671-2675.
31. Pestova, E., R. Beyer, N. P. Cianciotto, G. A. Noskin, and L. R. Peterson. 1999. Contribution of topoisomerass IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob. Agents Chemother. 43:2000-2004.
32. Pletz, M. W. R., L. McGee, J. Jorgensen, B. Beall, R. R. Facklam, C. G. Whitney, K. P. Klugman, and the Active Bacterial Core Surveillance Team. 2004. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob. Agents Chemother. 48:3491-3497.
33. Sahm, D. F., D. E. Peterson, I. A. Critchley, and C. Thorsberry. 2000. Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States. Antimicrob. Agents Chemother. 44:2521-2524.